JARDIANCE (Boehringer Ingelheim Pty Ltd)
Product name
JARDIANCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
182 (255 working days)
Active ingredients
empagliflozin
Registration type
EOI
Indication
JARDIANCE (film-coated tablet) is now also indicated in adults for the treatment of symptomatic heart failure with reduced ejection fraction, as an adjunct to standard of care therapy.